Palatin Technologies (PTN) Stock Price, Quote & News

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 495 2200

Fax: 609 495 2202

Website: palatin.com

Address:

Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, United States

prismmarketview Oct. 3 at 4:42 PM

PRISM Mid-Day Movers 🚀 AI tech & critical minerals led gains today: Brand Engagement Network ( $BNAI) +54% on strong volume & renewed momentum NioCorp ( $NB) +20%, nearing yearly highs on mineral project optimism Other movers: $HUMA +20%, $FEMY +16%, $PTN -44% https://prismmarketview.com/prism-mid-day-movers-ai-tech-critical-minerals-stocks-surge-as-bnai-jumps-54-and-niocorp-climbs-20/

0 · Reply

Stocks787 Oct. 1 at 3:32 PM

$PTN 🥴🥴🥴🥴😂😂😂 no

1 · Reply

Stocks787 Oct. 1 at 3:31 PM

$PTN $1.00

0 · Reply

HellenJune Sep. 30 at 5:11 PM

$PTN How many of you bought it by mistake (Peloton)?

0 · Reply

Stocks787 Sep. 29 at 7:25 PM

$PTN 1.00

1 · Reply

Warmark Sep. 27 at 1:02 AM

$PTN Yikes. Another RS coming by the end of 2026. No doubt about it. This company has zero going for it.

0 · Reply

DonDon79 Sep. 26 at 8:53 PM

$PTN when they will be coming back to NYSE? Cannot trade them at the moment.

0 · Reply

d_risk Sep. 23 at 10:39 PM

$PTN - PALATIN TECHNOLOGIES INC - 10K - Updated Risk Factors PTN’s 2025 risk factors spotlight ongoing going concern doubts, sharp cash decline, continued heavy losses, and uncertain profitability. Vyleesi’s sale brings delayed milestone hopes, while new Boehringer Ingelheim deals add revenue potential but with termination risks. Expanded disclosures stress regulatory, clinical, manufacturing, and commercialization hurdles, intense competition, reliance on third parties, and major dilution and delisting threats. #Biotechnology #PartnershipRisk #FinancialDistress #RegulatoryRisk #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/PTN/10-K/2025-09-23

0 · Reply

JOHNB21400 Sep. 23 at 4:28 PM

$PTN 10.50 and more

1 · Reply

JOHNB21400 Sep. 22 at 9:44 PM

$PTN Here we go. Awaiting conference call.

0 · Reply

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 5:20 PM EDT - 5 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 8:15 AM EDT - 5 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:00 AM EDT - 5 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 5, 2025, 7:30 AM EDT - 5 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Apr 29, 2025, 7:30 AM EDT - 5 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 17, 2025, 7:30 AM EDT - 6 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 14, 2025, 7:00 AM EDT - 6 months ago

Palatin Appeals NYSE American Notice of Delisting

Apr 10, 2025, 4:01 PM EDT - 6 months ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 7:30 AM EDT - 6 months ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Mar 31, 2025, 7:30 AM EDT - 6 months ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 28, 2025, 7:30 AM EDT - 6 months ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 25, 2025, 7:30 AM EDT - 6 months ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Feb 15, 2025, 5:41 AM EST - 8 months ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 13, 2025, 7:30 AM EST - 8 months ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 10, 2025, 4:00 PM EST - 8 months ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 7, 2025, 8:00 AM EST - 8 months ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 6, 2025, 7:30 AM EST - 8 months ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025, 7:30 AM EST - 8 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024, 7:30 AM EST - 10 months ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 16, 2024, 7:30 AM EST - 10 months ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Nov 25, 2024, 7:30 AM EST - 11 months ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 14, 2024, 12:49 PM EST - 11 months ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 7:30 AM EST - 11 months ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 8, 2024, 9:57 AM EST - 11 months ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 4, 2024, 7:30 AM EST - 11 months ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 7, 2024, 4:15 PM EDT - 1 year ago

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 1, 2024, 2:55 PM EDT - 1 year ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

May 15, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

May 2, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

$Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024$

Apr 8, 2024, 7:30 AM EDT - 1 year ago

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Feb 28, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 15, 2024, 2:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript

Feb 15, 2024, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Feb 9, 2024, 7:30 AM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Feb 5, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 1, 2024, 4:00 PM EST - 1 year ago

Palatin Announces Closing of $10 Million Registered Direct Offering

prismmarketview Oct. 3 at 4:42 PM

0 · Reply

Stocks787 Oct. 1 at 3:32 PM

$PTN 🥴🥴🥴🥴😂😂😂 no

1 · Reply

Stocks787 Oct. 1 at 3:31 PM

$PTN $1.00

0 · Reply

HellenJune Sep. 30 at 5:11 PM

$PTN How many of you bought it by mistake (Peloton)?

0 · Reply

Stocks787 Sep. 29 at 7:25 PM

$PTN 1.00

1 · Reply

Warmark Sep. 27 at 1:02 AM

$PTN Yikes. Another RS coming by the end of 2026. No doubt about it. This company has zero going for it.

0 · Reply

DonDon79 Sep. 26 at 8:53 PM

$PTN when they will be coming back to NYSE? Cannot trade them at the moment.

0 · Reply

d_risk Sep. 23 at 10:39 PM

0 · Reply

JOHNB21400 Sep. 23 at 4:28 PM

$PTN 10.50 and more

1 · Reply

JOHNB21400 Sep. 22 at 9:44 PM

$PTN Here we go. Awaiting conference call.

0 · Reply

WallStWireAds Sep. 22 at 1:37 PM

$PTN https://thefinanceherald.com/palatins-e5-5m-milestone-payment-signals-big-pharma-validation-for-this-8m-biotech-gem/

0 · Reply

WallStWireAds Sep. 22 at 11:31 AM

$PTN https://caplynx.io/5AMg95N

0 · Reply

Stocks787 Sep. 21 at 12:05 AM

$PTN 1.00 soon

0 · Reply

YoloAlfred Sep. 16 at 12:26 PM

$BIVI $SMMT $PTN $RXRX $SHPH how much cash on hand does BIVI have?

1 · Reply

CalculatedSwing Sep. 16 at 5:33 AM

$BIVI 🚨 $BIVI BULLISH BOMBSHELL! 🚀 At ~$1.90, this micro-cap ROCKET (mkt cap $14M) is primed to EXPLODE on SUNRISE-PD Phase 2 Parkinson's data late 2025 – targeting motor/non-motor wins w/ Bezisterim! Plus, Phase 3 Alzheimer's relaunch mid-2025, Long COVID trial early 2026, & BIV201 liver breakthrough (50% mortality reducer). Brookline PT $12 (6x upside)! New Neuralink/Mastercard/Apple advisory board = GAME-CHANGER. $12M cash fuels the fire – DILUTION DONE, now CATALYSTS GALORE! Don't fade this biotech BEAST! 📈 #BIVI #Parkinsons #Alzheimers #BullishAF 💎🙌 $SMMT $PTN $RXRX $SHPH

1 · Reply

JOHNB21400 Sep. 15 at 7:09 PM

$PTN The sentiment moved to buy. Earnings coming soon as well as news.

1 · Reply

Stocks787 Sep. 11 at 12:39 PM

$PTN 1.00

0 · Reply

Stocks787 Sep. 10 at 12:53 PM

$PTN PTNT

0 · Reply

Stocks787 Sep. 10 at 12:53 PM

$PTN 💩😳😳😳

0 · Reply

Stocks787 Sep. 10 at 10:00 AM

$PTN ?????

0 · Reply

Stocks787 Sep. 9 at 1:17 PM

$PTN 1.00 Soon

0 · Reply

Warmark Sep. 9 at 12:52 AM

$PTN Bankruptcy is on the way!

1 · Reply

Market Cap	2.45M
Revenue (ttm)	4.49M
Net Income (ttm)	-29.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-662.36%
Debt to Equity Ratio	0.00

Volume	14,571,800
Avg Vol	3,131,146
Day's Range	N/A - N/A
Shares Out	26.01M
Stochastic %K	5%
Beta	0.94
Analysts	Strong Sell
Price Target	$7.00